FDA Approves Kite’s Yescarta for Relapsed/Refractory Large B-cell Lymphoma

FDA Approves Kite’s Yescarta for Relapsed/Refractory Large B-cell Lymphoma

8 April 2022
FDA Approves Kite’s Yescarta for Relapsed/Refractory Large B-cell Lymphoma
The global biopharmaceutical company, Kite, a Gilead Company, has announced the FDA’s approval of their CAR-T cell therapy, Yescarta, for the treatment of adult patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More
Recent Stories
Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies
26 May 2022
Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies
The late-stage cell and gene
Umoja and Lupagen Collaboration Drives Improved Delivery for Next Generation <i data-src=
Virica Biotech Receives Funding from Canadian Government to Support the Re-Development of the Worlds First Ever Gene Therapy
18 May 2022
Virica Biotech Receives Funding from Canadian Government to Support the Re-Development of the Worlds First Ever Gene Therapy
Virica Biotech has announced collaboration
ASGCT: Highlights From the Program
16 May 2022
ASGCT: Highlights From the Program
Ryan Leahy summarizes what he’s
POPULAR NEWS ITEMS
Image
26 May 2022

Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies

Image
25 May 2022

Key Takeaways from ASGCT 2022

Image
24 May 2022

Umoja and Lupagen Collaboration Drives Improved Delivery for Next Generation in vivo CAR-T

FDA and European Commission Both Grant Orphan Designation to AviadoBio’s Gene Therapy Product Targeting Frontotemporal Dementia
27 April 2022
FDA and European Commission Both Grant Orphan Designation to AviadoBio’s Gene Therapy Product Targeting Frontotemporal Dementia
AviadoBio has announced both the
FDA Grants Third RMAT Designation to AlloVir’s T Cell Therapy – Targeting Viruses in Allogeneic Hematopoietic Cell Transplant Patients
21 April 2022
FDA Grants Third RMAT Designation to AlloVir’s T Cell Therapy – Targeting Viruses in Allogeneic Hematopoietic Cell Transplant Patients
AlloVir, has announced the FDA
Load More News
RECOMENDED TOPICS
CAR-X
Cell Therapy
Collaborations, Mergers & Acquisitions
Partnering
Finance & Investment
Gene Therapy
GMP
Manufacturing
Scaling Up
Gene Editing
Skills, Talent & Development
Viral/Non-Viral Vectors
Regulatory & Standards
Allogeneic
Clinical Trials
Cell-Based IO
Industry Insights
Patient Access & Engagement
Supply Chain
CMC
Automation & Digitisation
Logistics
Stem Cells
Tissue Engineering
NKx
Point of Care
Reimbursement
Uncategorized
POPULAR NEWS ITEMS
Image

Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies

Image

How Collaboration and Simplification is Key to Solving Industry-Wide Efficacy and Supply Chain Challenges

Image

Key Takeaways from ASGCT 2022